Pulse Biosciences Presents Long-Term Data on Thyroid Nodule Treatment at Key Meeting — Pulse Biosciences, Inc.

Event summary

Pulse Biosciences' nPulse Vybrance System to be featured in multiple presentations at the North American Society for Interventional Thyroidology meeting on March 6-7, 2026.
Long-term follow-up data (up to 22 months) from the feasibility study of benign thyroid nodules treatment to be presented by Prof. Stefano Spiezia.
Product theatre presentation to include roundtable discussion with top nPulse users on technology and case studies.

The big picture

Pulse Biosciences is positioning its nPulse Vybrance System as a non-thermal ablation solution for benign thyroid nodules, aiming to disrupt traditional thermal ablation methods. The presentation of long-term data at a key industry meeting underscores the company's strategy to validate its technology through clinical evidence and engage with the medical community. Success in this space could open doors to broader applications in other medical fields.

What we're watching

Clinical Validation: How the long-term data from the feasibility study will impact the adoption of nPulse Vybrance technology for benign thyroid nodules.
Market Expansion: Whether Pulse Biosciences can leverage this presentation to expand into other markets beyond thyroid treatment, such as atrial fibrillation.
Regulatory Pathway: The pace at which Pulse Biosciences can advance its nsPFA technology through regulatory approvals based on the presented data.